Form 4: ImmuCell Director Acquires 10,000 Stock Options
SEC Form 4 Filing
Gloria F. Basse, a director of ImmuCell Corp, acquired 10,000 non-qualified stock options on September 20, 2024, at an exercise price of $3.60.
Summary
- On September 20, 2024, Gloria F. Basse, a director of ImmuCell Corporation, acquired 10,000 non-qualified stock options.
- The exercise price for these options is $3.60.
- The options are exercisable from September 20, 2027, and expire on September 20, 2029.
- The transaction was reported on September 24, 2024.
Sentiment
Score: 5
Explanation: Neutral. This is a routine disclosure of stock option acquisition by a director, with no inherent positive or negative implications.
Industry Context
This is a standard SEC Form 4 filing, indicating a change in beneficial ownership by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.
Stakeholder Impact
- The acquisition of stock options by a director may signal confidence in the company's future prospects, potentially impacting shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 09/20/2024 | Date of earliest transaction: Acquisition of 10,000 non-qualified stock options. |
| 09/20/2027 | Options become exercisable. |
| 09/20/2029 | Options expiration date. |
| 09/24/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.